Cytokinetics (CYTK) Cash & Current Investments (2010 - 2026)

Cytokinetics (CYTK) has reported Cash & Current Investments for 17 consecutive years, with $818.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 12.79% year-over-year to $818.6 million; the TTM figure through Mar 2026 stood at $818.6 million (down 12.79% YoY), while the FY2025 annual figure was $882.2 million, down 18.04% from the prior year.
• Cash & Current Investments eased to $818.6 million in Q1 2026 per CYTK's latest filing, from $882.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.1 billion in Q4 2024 and bottomed at $539.6 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $791.7 million across 5 years, with a median of $818.6 million in 2026.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 37.81% — and 2024, when it jumped 87.55%.
• Cytokinetics' Cash & Current Investments stood at $784.2 million in 2022, then retreated by 21.55% to $615.2 million in 2023, then soared by 74.97% to $1.1 billion in 2024, then declined by 18.04% to $882.2 million in 2025, then decreased by 7.22% to $818.6 million in 2026.
• Business Quant data shows CYTK's Cash & Current Investments at $818.6 million in Q1 2026, $882.2 million in Q4 2025, and $962.5 million in Q3 2025.